LUV TES

A 44-residue synthetic peptide carrying an N-terminal trans-3-hexenoyl group, studied at a class B GPCR.

View Luv TES in the store

Molecular Profile

Type
Synthetic peptide (acylated, 44 residues)
Molecular formula
C221H366N72O67S
Molecular weight
~5,136 g/mol
CAS number
218949-48-5
Amino acids
44
Modification
Full GHRH(1-44) with an N-terminal trans-3-hexenoyl group; C-terminal amide.

Mechanism & Target Class

A 44-residue synthetic peptide corresponding to the GRF(1-44) sequence of a hypothalamic peptide, carrying an N-terminal trans-3-hexenoyl group and a C-terminal amide. It has been studied in complex with a class B GPCR. The N-terminal trans-3-hexenoyl modification distinguishes its structure from the unmodified parent sequence and confers added resistance to N-terminal proteolysis.

Storage & Handling

Lyophilized
-20°C (-80°C extended); typically stable 24-36 months desiccated.
Handling
Avoid freeze-thaw; aliquot; protect from light and moisture. Contains an oxidation-sensitive methionine.

Primary Database

PubChem CID 16137839 ↗

References (22)

  1. Reviews

    1

    Spooner LM. (2012). Ann Pharmacother

    DOI: 10.1345/aph.1Q629PubMed 22298602

  2. 2

    Dhillon S. (2011). Drugs

    PubMed 21668043

  3. 3

    Tomlinson B, Hu M. (2006). Expert Opin Investig Drugs

    PubMed 17086939

  4. 4

    Bedimo R. (2011). HIV AIDS (Auckl)

    DOI: 10.2147/HIV.S14561PubMed 22096409

  5. Clinical

    5

    Ellis RJ, et al. (2025). J Infect Dis

    DOI: 10.1093/infdis/jiaf012PubMed 39813152

  6. 6

    Russo SC, et al. (2024). AIDS

    DOI: 10.1097/QAD.0000000000003965PubMed 38905488

  7. 7

    Fourman LT, et al. (2020). JCI Insight

    DOI: 10.1172/jci.insight.140134PubMed 32701508

  8. 8

    Stanley TL, et al. (2019). Lancet HIV

    PubMed 31611038

  9. 9

    Clemmons DR, et al. (2017). PLOS ONE

    DOI: 10.1371/journal.pone.0179538PubMed 28617838

  10. 10

    Stanley TL, et al. (2014). JAMA

    DOI: 10.1001/jama.2014.8531

  11. 11

    Friedman SD, et al. (2013). JAMA Neurol

    DOI: 10.1001/jamaneurol.2013.1425PubMed 23689947

  12. 12

    Baker LD, et al. (2012). Arch Neurol

    DOI: 10.1001/archneurol.2012.1970PubMed 22869065

  13. 13

    Makimura H, et al. (2012). J Clin Endocrinol Metab

    PubMed 23015655

  14. 14

    Stanley TL, et al. (2012). Clin Infect Dis

    DOI: 10.1093/cid/cis251PubMed 22495074

  15. 15

    Falutz J, et al. (2010). J Clin Endocrinol Metab

    PubMed 20554713

  16. 16

    Falutz J, et al. (2010). J Acquir Immune Defic Syndr

    DOI: 10.1097/QAI.0b013e3181cbdaffPubMed 20101189

  17. 17

    Falutz J, et al. (2008). AIDS

    DOI: 10.1097/QAD.0b013e32830a5058PubMed 18690162

  18. 18

    Falutz J, et al. (2007). NEJM

    DOI: 10.1056/NEJMoa072375PubMed 18057338

  19. 19

    Falutz J, et al. (2005). AIDS

    DOI: 10.1097/01.aids.0000180099.35146.30PubMed 16052083

  20. Primary research

    20

    Stanley TL, et al. (2011). J Clin Endocrinol Metab

    DOI: 10.1210/jc.2010-1587PubMed 20943777

  21. 21

    González-Sales M, et al. (2015). Clin Pharmacokinet

    DOI: 10.1007/s40262-014-0202-xPubMed 25358450

  22. 22

    González-Sales M, et al. (2015). J Pharmacokinet Pharmacodyn

    DOI: 10.1007/s10928-015-9416-2PubMed 25895899